Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase

Jin-Hua Liang1, Xin-Yu Zhang1, Lin-Tao Bi2

  • 1Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.

BMC Medicine
|July 10, 2026
PubMed
Summary

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Signal transduction and targeted therapy·2026
Same author

BTG2 knockdown attenuates oxygen-glucose deprivation/reoxygenation-induced injury and apoptosis in PC12 cells: an effect associated with MAPK pathway inhibition.

Molecular biology reports·2026
Same author

Integrating 3D phenotyping and functional-structural plant models for crop ideotype breeding.

Nature communications·2026
Same author

Immune subtyping of colorectal adenoma identifies a subtype with activated adaptive immunity ahead of progressing to cancer.

Discover oncology·2026
Same author

Fe/Mg-LDH modified biochar for heavy metal soil remediation: Effects on microbial community structure and metabolic activity.

Journal of hazardous materials·2026
Same author

Biodegradation of cyano liquid crystal monomers by an aerobic enrichment culture: Key degraders and interspecies synergistic mechanisms.

Water research·2026

This study shows a new liposome-based regimen is effective for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The treatment demonstrated promising response rates and survival, with a manageable safety profile.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) presents a significant challenge in patient care.
  • Conventional treatments for R/R DLBCL have limitations, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel liposome-mitoxantrone hydrochloride (Lipo-MIT)-based rituximab with mitoxantrone/ifosfamide/mesna/etoposide (R-MINE) regimen.
  • To assess the impact of adding a targeted agent to the Lipo-MIT-based R-MINE regimen in R/R DLBCL patients.

Main Methods:

  • A multicenter, phase II clinical trial (NCT05784987) was conducted.
  • Patients with R/R DLBCL received the Lipo-MIT-based R-MINE regimen for up to four 21-day cycles.
  • The addition of a targeted agent was individualized based on prior treatment resistance and molecular subtype.
Keywords:
R-MINEdiffuse large B-cell lymphomagenetic subtypemitoxantrone hydrochloride liposomerelapsed or refractorytargeted therapy

Related Experiment Videos

Main Results:

  • An objective response rate (ORR) of 76.4% was observed in 55 efficacy-evaluable patients.
  • The complete response rate was 52.7%, with a median progression-free survival (PFS) of 17.5 months.
  • Grade ≥3 treatment-related adverse events (TRAEs) occurred in 46.7% of patients, primarily neutropenia, with no serious TRAEs or deaths.

Conclusions:

  • The Lipo-MIT-based R-MINE regimen demonstrates encouraging efficacy in treating R/R DLBCL.
  • The regimen exhibits a manageable safety profile, suggesting its potential as a valuable treatment option.
  • Further validation studies are warranted to confirm these findings.